Efficient production of cloned bovine embryos using cdc2 kinase inhibitor.
This study was carried out to compare the effects of the combination of ionomycin with a H1-histone kinase inhibitor (dimethylaminopurine, DMAP) or cdc2 kinase inhibitor (sodium pyrophosphate, SPP) on the development of reconstituted bovine eggs. For this study, the enucleated bovine oocytes were injected with a presumptive primordial germ cell pre-treated with 1% sodium citrate, and randomly allocated into three activation groups: Group 1 (ionomycin 5 microm, 5 min), Group 2 (ionomycin + DMAP 1.9 mm, 3 h), and Group 3 (ionomycin + SPP 2 mm, 3 h). The reconstituted eggs were compared on the rates of cleavage and development with the blastocyst stage and the ploidy of embryos at 96 h post-activation. Cleavage rates and blastocyst development in Groups 1, 2 and 3 were 7 and 0%, 63 and 17%, and 53 and 14%, respectively. The chromosomal composition differed significantly (p < 0.05) among treatments. Although the embryos in Group 1 had significantly lower developments, 60% of embryos evaluated had diploid chromosomal sets. In contrast, approximately 60% of embryos in Group 2 had abnormal ploidy (21% polyploid and 38% mixoploid). In Group 3, the appearance of abnormal chromosome sets was reduced with the proportion of diploid embryos being increased to 86% (19 of 22), significantly higher (p < 0.05) than in Group 2. It can be concluded that the use of SPP with ionomycin reduces greatly the incidence of chromosomal abnormalities, and may be applicable for the activation of nuclear transplant bovine embryos.
Yoo
J G
JG
College of Veterinary Medicine, Gyeongsang National University, Chinju, Korea.
Choe
S Y
SY
Rho
G J
GJ
D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000818:Animals; D001755:Blastocyst / Q000187:drug effects* / Q000502:physiology; D016203:CDC2 Protein Kinase / Q000037:antagonists & inhibitors*; D002417:Cattle; D002999:Clone Cells / Q000187:drug effects* / Q000502:physiology; D011756:Diphosphates / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D015759:Ionomycin / Q000008:administration & dosage / Q000494:pharmacology*; D011247:Pregnancy; D006656:Protamine Kinase / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
D011756:Diphosphates; D015759:Ionomycin; C001020:N(6),N(6)-dimethyladenine; D006656:Protamine Kinase; D016203:CDC2 Protein Kinase; D000225:Adenine; C003319:sodium pyrophosphate